Relay Therapeutics
RLAY
115 hedge funds and large institutions have $3.64B invested in Relay Therapeutics in 2020 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 32 increasing their positions, 20 reducing their positions, and 11 closing their positions.
191% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 11
60% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 20
22% more funds holding
Funds holding: 94 → 115 (+21)
0% more funds holding in top 10
Funds holding in top 10: 11 → 11 (0)
0% less capital invested
Capital invested by funds: $3.64B → $3.64B (-$155K)
2.91% less ownership
Funds ownership: 100.36% → 97.46% (-2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$49.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$38.4M |
| 3 |
Goldman Sachs
New York
|
+$26.3M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$10.4M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$9.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$252M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$17.6M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$13.8M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$10.6M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$9.69M |
RLAY Hedge Fund Activity: Q4 2020 in Review
115 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q4 2020, worth a combined $3.64B — down 0% from $3.64B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new RLAY positions and 11 closed out — a net gain of 21 holders — while 32 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $49.3M. The largest seller was Baillie Gifford & Co, cutting an estimated $252M.
- 115 institutional investors held Relay Therapeutics (RLAY) as of Q4 2020, up from 94 in Q3 2020.
- Funds reported $3.64B of Relay Therapeutics stock for Q4 2020, down 0% quarter-over-quarter.
- 32 funds opened new Relay Therapeutics positions in Q4 2020 and 11 closed out, a net change of +21 holders.
- The largest Relay Therapeutics buyer in Q4 2020 was BlackRock, an estimated $49.3M added.
- The largest Relay Therapeutics seller in Q4 2020 was Baillie Gifford & Co, an estimated $252M sold.
Based on aggregated 13F filings for Q4 2020.